Program Overview

Through the GARDASIL Access Program, Merck & Co. Inc, (Whitehouse Station, NJ, USA) has pledged to donate at least 3 million doses of GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant] to qualifying organizations and institutions in developing countries, where more than 85% of the world's cervical cancer cases occur.

The GARDASIL Access Program has helped enable organizations and institutions in eligible lowest income countries to gain operational experience designing and implementing human papillomavirus (HPV) vaccination projects, with the goal of supporting the development of successful child and adolescent immunization models. 

The operational experiences and lessons learned by participants in the program are widely disseminated in an effort to contribute to the public knowledge base on HPV vaccine access and child/adolescent immunization models in lowest income countries.

The GARDASIL Access Program is made possible by a pledge from Merck & Co., Inc. [Whitehouse Station, New Jersey, U.S.A.]  and is managed by Axios Healthcare Development (AHD), a US non-profit organization, with strategic guidance provided by the independent GARDASIL Access Program Advisory Board comprised of international public health experts. 

Click here to learn more about the participating organizations and institutions that have completed or are currently implementing HPV vaccination projects supported by the GARDASIL Access Program.